

Kenneth R Cooke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11915280/publications.pdf>

Version: 2024-02-01

128
papers

8,447
citations

36303

51
h-index

46799

89
g-index

132
all docs

132
docs citations

132
times ranked

6972
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary surveillance in pediatric hematopoietic stem cell transplant: A multinational multidisciplinary survey. <i>Cancer Reports</i> , 2022, 5, e1501.	1.4	5
2	Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort. <i>Bone Marrow Transplantation</i> , 2022, 57, 279-281.	2.4	2
3	Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. <i>Blood</i> , 2022, 139, 608-623.	1.4	42
4	Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. <i>JCI Insight</i> , 2022, 7, .	5.0	12
5	A biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 1866-1878.	5.2	4
6	Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. <i>Blood Advances</i> , 2022, 6, 2520-2534.	5.2	19
7	Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	4
8	Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. <i>Annals of the American Thoracic Society</i> , 2021, 18, 381-394.	3.2	26
9	Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes. <i>Journal of Clinical Immunology</i> , 2021, 41, 414-426.	3.8	12
10	Human Multipotent Adult Progenitor Cells Effectively Reduce Graft-vs-Host Disease While Preserving Graft-Vs-Leukemia Activity. <i>Stem Cells</i> , 2021, 39, 1506-1519.	3.2	4
11	Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups. <i>Blood</i> , 2020, 135, 1428-1437.	1.4	15
12	Outcomes of pediatric patients with oncologic disease or following hematopoietic stem cell transplant supported on extracorporeal membrane oxygenation: The PEDECOR experience. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28403.	1.5	22
13	Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 822-836.	2.5	53
14	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e94-e100.	2.0	3
15	Cryo-imaging of Stem Cell Biodistribution in Mouse Model of Graft-Versus-Host-Disease. <i>Annals of Biomedical Engineering</i> , 2020, 48, 1702-1711.	2.5	11
16	Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. <i>Bone Marrow Transplantation</i> , 2019, 54, 383-392.	2.4	30
17	Chemokines and Graft-Versus-Host Disease. , 2019, , 323-347.		0
18	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. <i>Lancet Haematology</i> , 2019, 6, e183-e193.	4.6	111

#	ARTICLE	IF	CITATIONS
19	Noninfectious Pulmonary Complications. , 2019, , 393-401.		7
20	The role of continuous renal replacement therapy in the management of acute kidney injury associated with sinusoidal obstruction syndrome following hematopoietic cell transplantation. <i>Pediatric Transplantation</i> , 2018, 22, e13139.	1.0	17
21	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1022-1028.	2.0	29
22	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1099-1102.	2.0	61
23	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.8	47
24	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2056-2064.	2.0	32
25	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 612-617.	2.0	17
26	Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice. <i>Blood</i> , 2017, 129, 246-256.	1.4	14
27	Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017, 102, 932-940.	3.5	27
28	Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1. <i>Pediatric Critical Care Medicine</i> , 2017, 18, S50-S57.	0.5	17
29	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. <i>Blood</i> , 2017, 129, 1389-1393.	1.4	69
30	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2127-2136.	2.0	17
31	Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26257.	1.5	22
32	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328
33	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 325-332.	2.0	61
34	Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 895-901.	2.0	64
35	Automatic Stem Cell Detection in Microscopic Whole Mouse Cryo-Imaging. <i>IEEE Transactions on Medical Imaging</i> , 2016, 35, 819-829.	8.9	20
36	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 112-118.	2.0	37

#	ARTICLE	IF	CITATIONS
37	Idiopathic pneumonia syndrome following hematopoietic stem cell transplantation. <i>Journal of Pediatric Intensive Care</i> , 2015, 03, 147-157.	0.8	8
38	Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation. <i>Blood</i> , 2015, 125, 2435-2444.	1.4	73
39	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 780-792.	2.0	124
40	The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1251-1257.	2.0	14
41	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1479-1487.	2.0	173
42	Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1046-1053.	2.0	133
43	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 67-73.	2.0	62
44	Human Mesenchymal Stromal Cells Attenuate Graft-Versus-Host Disease and Maintain Graft-Versus-Leukemia Activity Following Experimental Allogeneic Bone Marrow Transplantation. <i>Stem Cells</i> , 2015, 33, 601-614.	3.2	76
45	Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA). <i>Blood</i> , 2015, 126, 2031-2031.	1.4	14
46	Route of delivery influences biodistribution of human bone marrow-derived mesenchymal stromal cells following experimental bone marrow transplantation. <i>Journal of Stem Cells and Regenerative Medicine</i> , 2015, 11, 34-43.	2.2	6
47	A "Window of Opportunity" for Patients with Late-Onset Pulmonary Dysfunction after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 291-292.	2.0	10
48	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 858-864.	2.0	78
49	Novel T lymphocyte proliferation assessment using whole mouse cryo-imaging. <i>Proceedings of SPIE</i> , 2014, , .	0.8	3
50	Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation. <i>Pediatric Oncology</i> , 2014, , 77-102.	0.5	1
51	Randomized, Double Blind, Placebo-Controlled Trial of a TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) After Allogeneic Stem Cell Transplant (SCT). A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S169.	2.0	4
52	Chemokines and graft-versus-host disease. , 2013, , 393-424.		6
53	Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. <i>Blood</i> , 2013, 122, 3871-3878.	1.4	141
54	Human Biomarker Discovery and Predictive Models for Disease Progression for Idiopathic Pneumonia Syndrome Following Allogeneic Stem Cell Transplantation. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.015479.	3.8	37

#	ARTICLE	IF	CITATIONS
55	National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 334-347.	2.0	82
56	Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Subacute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1044-1054.	2.0	48
57	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. <i>Blood</i> , 2012, 120, 733-733.	1.4	4
58	Comorbidity Index (CI) in Autologous Hematopoietic Cell Transplantation (HCT) for Malignant Diseases: Validation of the HCT-CI. <i>Blood</i> , 2012, 120, 814-814.	1.4	10
59	The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Can Prospectively Discriminate Risks Affecting Overall Survival in Pediatric and Adult Patients with Non-Malignant Diseases. <i>Blood</i> , 2012, 120, 737-737.	1.4	11
60	The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 762-762.	1.4	1
61	Translational Research Efforts in Biomarkers and Biology of Early Transplant-Related Complications. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S101-S108.	2.0	5
62	National Cancer Institute“National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Long-Term Organ Damage and Dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1573-1584.	2.0	76
63	An Official American Thoracic Society Research Statement: Noninfectious Lung Injury after Hematopoietic Stem Cell Transplantation: Idiopathic Pneumonia Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1262-1279.	5.6	271
64	Charlson Comorbidity Index (CCI) Not Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Successfully Predicts Transplant Related Mortality and Post-Transplant Outcomes in Elderly Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. <i>Blood</i> , 2011, 118, 3006-3006.	1.4	0
65	A role for lymphotoxin in GVHD and GVL. <i>Blood</i> , 2010, 115, 3-4.	1.4	2
66	Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis. <i>Journal of Experimental Medicine</i> , 2010, 207, 2507-2519.	8.5	60
67	Regenerative Stromal Cell Therapy in Allogeneic Hematopoietic Stem Cell Transplantation: Current Impact and Future Directions. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 891-906.	2.0	39
68	Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation: A shifting Paradigm for T Cell Allo-activation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 598-611.	2.0	16
69	Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT).. <i>Blood</i> , 2010, 116, 3486-3486.	1.4	2
70	Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis. <i>Journal of Cell Biology</i> , 2010, 191, i4-i4.	5.2	0
71	Etanercept Clearance during an in vitro Model of Continuous Venovenous Hemofiltration. <i>Blood Purification</i> , 2009, 28, 348-353.	1.8	2
72	Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease. <i>Current Opinion in Pediatrics</i> , 2009, 21, 30-38.	2.0	23

#	ARTICLE	IF	CITATIONS
73	A biomarker panel for acute graft-versus-host disease. <i>Blood</i> , 2009, 113, 273-278.	1.4	348
74	Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.. <i>Blood</i> , 2009, 114, 43-43.	1.4	0
75	The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation. <i>Pediatric Blood and Cancer</i> , 2008, 50, 911-914.	1.5	6
76	The Contribution of Endothelial Activation and Injury to End-Organ Toxicity following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 23-32.	2.0	79
77	A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 385-396.	2.0	21
78	The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2008, 112, 3073-3081.	1.4	117
79	Lung Injury after Hematopoietic Stem Cell Transplantation. , 2008, , 495-536.		0
80	CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. <i>Blood</i> , 2007, 110, 3447-3455.	1.4	76
81	Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 749-759.	2.0	170
82	Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease. <i>Experimental Hematology</i> , 2007, 35, 155-163.	0.4	19
83	The Lung as a Target Organ of Graft-Versus-Host Disease. <i>Seminars in Hematology</i> , 2006, 43, 42-52.	3.4	57
84	Pulmonary toxicity following hematopoietic cell transplantation: Is the lung a target organ of graft-versus-host disease?. <i>Current Opinion in Organ Transplantation</i> , 2006, 11, 69-77.	1.6	4
85	Critical Role of Prostaglandin E2 Overproduction in Impaired Pulmonary Host Response following Bone Marrow Transplantation. <i>Journal of Immunology</i> , 2006, 177, 5499-5508.	0.8	78
86	Changes in TNFR1 Levels in the First Week Post-Myeloablative HSCT Correlate with Severity and Incidence of GVHD and 1y TRM.. <i>Blood</i> , 2006, 108, 37-37.	1.4	1
87	A Role for CD54 (Intercellular Adhesion Molecule-1) in Leukocyte Recruitment to the Lung During the Development of Experimental Idiopathic Pneumonia Syndrome. <i>Transplantation</i> , 2005, 79, 536-542.	1.0	21
88	Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. <i>Blood</i> , 2005, 105, 2249-2257.	1.4	44
89	Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again. <i>Pediatric Transplantation</i> , 2005, 9, 25-36.	1.0	29
90	Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 680-687.	2.0	89

#	ARTICLE	IF	CITATIONS
91	Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation.. Blood, 2005, 106, 3107-3107.	1.4	0
92	Host Dendritic Cells Alone Are Sufficient to Initiate Acute Graft-versus-Host Disease. Journal of Immunology, 2004, 172, 7393-7398.	0.8	225
93	Blockade of CXCR3 Receptor:Ligand Interactions Reduces Leukocyte Recruitment to the Lung and the Severity of Experimental Idiopathic Pneumonia Syndrome. Journal of Immunology, 2004, 173, 2050-2059.	0.8	95
94	Graft-versus-host disease of the skin: life and death on the epidermal edge. Biology of Blood and Marrow Transplantation, 2004, 10, 366-372.	2.0	34
95	Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation, 2004, 10, 461-472.	2.0	34
96	A Role for Tumor Necrosis Factor- α -Mediated Endothelial Apoptosis in the Development of Experimental Idiopathic Pneumonia Syndrome. Transplantation, 2004, 78, 494-502.	1.0	53
97	A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood, 2004, 103, 2417-2426.	1.4	86
98	Donor-derived TNF- α regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood, 2004, 104, 586-593.	1.4	85
99	Survival Following Etanercept Therapy for the Treatment of Idiopathic Pneumonia Syndrome Post Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 354-354.	1.4	5
100	Pathophysiology of Lung Injury After Hematopoietic Stem Cell Transplantation. , 2004, , 271-295.		0
101	The Use of Laparoscopic Liver Biopsies in Pediatric Patients with Hepatic Dysfunction Following Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 1147-1147.	1.4	0
102	IL-13 - Predictor of or Protector from Acute Graft Versus Host Disease?.. Blood, 2004, 104, 3070-3070.	1.4	0
103	CCR1 Expression on Donor Leukocytes Is Critical to the Development of Graft Versus Host Disease after Allogeneic SCT.. Blood, 2004, 104, 3067-3067.	1.4	0
104	The Pathophysiology of Acute Graft-versus-Host Disease. International Journal of Hematology, 2003, 78, 181-187.	1.6	185
105	Role of CXCR3-induced donor T-cell migration in acute GVHD. Experimental Hematology, 2003, 31, 897-902.	0.4	152
106	Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect. Biology of Blood and Marrow Transplantation, 2003, 9, 592-603.	2.0	19
107	Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood, 2003, 101, 2877-2885.	1.4	65
108	Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood, 2003, 102, 429-435.	1.4	97

#	ARTICLE	IF	CITATIONS
109	Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 ⁺ dendritic cells and reduces experimental acute graft-versus-host disease. <i>Blood</i> , 2002, 99, 1825-1832.	1.4	72
110	Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. <i>Blood</i> , 2002, 100, 3429-3431.	1.4	37
111	Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 395-400.	2.0	117
112	Acute graft-versus-host disease does not require alloantigen expression on host epithelium. <i>Nature Medicine</i> , 2002, 8, 575-581.	30.7	495
113	The role of endotoxin and the innate immune response in the pathophysiology of acute graft-versus-host disease. <i>Journal of Endotoxin Research</i> , 2002, 8, 441-448.	2.5	65
114	LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. <i>Journal of Clinical Investigation</i> , 2001, 107, 1581-1589.	8.2	258
115	Hyporesponsiveness of Donor Cells to Lipopolysaccharide Stimulation Reduces the Severity of Experimental Idiopathic Pneumonia Syndrome: Potential Role for a Gut-Lung Axis of Inflammation. <i>Journal of Immunology</i> , 2000, 165, 6612-6619.	0.8	73
116	The p55 TNF Receptor Plays a Critical Role in T Cell Alloreactivity. <i>Journal of Immunology</i> , 2000, 164, 656-663.	0.8	130
117	TUMOR NECROSIS FACTOR- α NEUTRALIZATION REDUCES LUNG INJURY AFTER EXPERIMENTAL ALLOGENEIC BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 2000, 70, 272-279.	1.0	120
118	Granulocyte Colony-Stimulating Factor-Mobilized Allogeneic Stem Cell Transplantation Maintains Graft-Versus-Leukemia Effects Through a Perforin-Dependent Pathway While Preventing Graft-Versus-Host Disease. <i>Blood</i> , 1999, 93, 4071-4078.	1.4	108
119	Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease. <i>Blood</i> , 1999, 94, 825-831.	1.4	168
120	PRETRANSPLANT CHEMOTHERAPY REDUCES INFLAMMATORY CYTOKINE PRODUCTION AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1999, 67, 1478-1480.	1.0	25
121	Differential roles of IL-1 and TNF- α on graft-versus-host disease and graft versus leukemia. <i>Journal of Clinical Investigation</i> , 1999, 104, 459-467.	8.2	229
122	IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. <i>Journal of Clinical Investigation</i> , 1999, 104, 317-325.	8.2	159
123	Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease. <i>Blood</i> , 1999, 94, 825-831.	1.4	8
124	Host Reactive Donor T Cells Are Associated With Lung Injury After Experimental Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 2571-2580.	1.4	114
125	Host Reactive Donor T Cells Are Associated With Lung Injury After Experimental Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 2571-2580.	1.4	18
126	Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines. <i>Blood</i> , 1997, 90, 3204-3213.	1.4	765

#	ARTICLE	IF	CITATIONS
127	The Immunopathophysiology of Acute Graftâ€Versusâ€Hostâ€Disease. Stem Cells, 1996, 14, 473-489.	3.2	185
128	TRANSPLANTATION OF POLARIZED TYPE 2 DONOR T CELLS REDUCES MORTALITY CAUSED BY EXPERIMENTAL GRAFT-VERSUS-HOST DISEASE1. Transplantation, 1996, 62, 1278-1285.	1.0	57